UPDATE: ActivX Biosciences Raises $20M; Plans to Double Staff, Expand Platform | GenomeWeb

NEW YORK, July 10 - With $20 million from a private placement that closed Tuesday, ActivX Biosciences plans to double its scientific staff and build up its capabilities for applying its chemistry-based proteomics platform to drug discovery, chief operating officer Robert Hillman told GenomeWeb Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.